HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer.

AbstractBACKGROUND:
Prognostic factors in metastatic breast cancer continue to be identified. Previous adjuvant chemotherapy appeared to have poor prognosis in some studies but, despite this, the prior use of anthracyclines in the adjuvant setting has not been clearly established as an adverse prognostic factor once metastatic disease develops.
PATIENTS AND METHODS:
Patients (n = 1,436) with stages I-IIIa breast cancer were surgically treated with/without radiotherapy and/or systemic adjuvant treatment. Of these, 297 patients who relapsed with metastatic disease constitute the sample population of this retrospective study. Survival, as a function of time since diagnosis of metastatic disease, was assessed in relation to the following factors: age, size of the primary tumor, grade, number of positive axillary nodes, type of surgery, type of adjuvant treatment administered, time to relapse, number of metastatic sites, presence of visceral metastases and type of treatment employed at the time of relapse.
RESULTS:
In multivariable analysis three factors remained significant predictors of short survival time: more than 1 site of metastases (p = 0.00003), shorter time to relapse (p = 0.003) and the previous administration of anthracyclines as adjuvant therapy (p = 0.005).
CONCLUSIONS:
The prior use of adjuvant anthracyclines, with other known clinical prognostic factors, confers a poorer outcome in metastatic disease, perhaps as a result of resistant clones selection or by induction of de novo resistance.
AuthorsE Alba, N Ribelles, I Sevilla, A Rueda, L Alonso, A Marquez, I Ruiz, J Miramón
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 66 Issue 1 Pg. 33-9 (Mar 2001) ISSN: 0167-6806 [Print] Netherlands
PMID11368408 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
Topics
  • Antibiotics, Antineoplastic (therapeutic use)
  • Breast Neoplasms (drug therapy, mortality, pathology)
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Predictive Value of Tests
  • Prognosis
  • Retrospective Studies
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: